{"id":"NCT03048422","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","briefTitle":"Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants","officialTitle":"Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-19","primaryCompletion":"2020-10-03","completion":"2020-10-03","firstPosted":"2017-02-09","resultsPosted":"2021-11-10","lastUpdate":"2022-11-21"},"enrollment":643,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infections"],"interventions":[{"type":"DRUG","name":"Dolutegravir","otherNames":["DTG"]},{"type":"DRUG","name":"Emtricitabine/tenofovir alafenamide","otherNames":["FTC/TAF"]},{"type":"DRUG","name":"Emtricitabine/tenofovir disoproxil fumarate","otherNames":["FTC/TDF"]},{"type":"DRUG","name":"Efavirenz/emtricitabine/tenofovir disoproxil fumarate","otherNames":["EFV/FTC/TDF"]}],"arms":[{"label":"Arm 1: Maternal DTG+FTC/TAF","type":"EXPERIMENTAL"},{"label":"Arm 2: Maternal DTG+FTC/TDF","type":"EXPERIMENTAL"},{"label":"Arm 3: Maternal EFV/FTC/TDF","type":"ACTIVE_COMPARATOR"},{"label":"Arm 1 Infants","type":"NO_INTERVENTION"},{"label":"Arm 2 Infants","type":"NO_INTERVENTION"},{"label":"Arm 3 Infants","type":"NO_INTERVENTION"}],"summary":"The purpose of this study was to compare the virologic efficacy and safety of three antiretroviral (ARV) regimens, dolutegravir plus emtricitabine/tenofovir alafenamide, dolutegravir plus emtricitabine/tenofovir disoproxil fumarate, and efavirenz/emtricitabine/tenofovir disoproxil fumarate in pregnant women living with HIV-1 and to compare the safety of these regimens for their infants.","primaryOutcome":{"measure":"Percentage of Mothers With HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery","timeFrame":"Delivery","effectByArm":[{"arm":"Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF","deltaMin":97.5,"sd":null},{"arm":"Arm 3: Maternal EFV/FTC/TDF","deltaMin":91,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.005"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":5},"locations":{"siteCount":21,"countries":["United States","Botswana","Brazil","India","South Africa","Tanzania","Thailand","Uganda","Zimbabwe"]},"refs":{"pmids":["33812487","39250651","39219495","38877762","37167996"],"seeAlso":["http://impaactnetwork.org/studies/impaact2010","http://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-tables","http://intergrowth21.tghn.org/standards-tools/","http://www.fda.gov/files/drugs/published/Human-Immunodeficiency-Virus-1-Infection--Developing-Antiretroviral-Drugs-for-Treatment.pdf","http://pubmed.ncbi.nlm.nih.gov/21800414/","http://www-users.med.cornell.edu/~spon/picu/calc/crclschw.htm"]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":217},"commonTop":["Creatinine renal clearance decreased","Blood creatinine increased","Haemoglobin decreased","Neutrophil count decreased","Alanine aminotransferase increased"]}}